Literature DB >> 406098

Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use.

D T Danahy, W S Aronow.   

Abstract

In a randomized, double-blind, crossover study, 19 patients with angina were exercised 2 min after 0.4 mg sublingual nitroglycerin and after sublingual placebo and before and 1, 3, and 5 hours after oral isosorbide dinitrate (ISDN) and oral placebo. After initial testing, patients took the dose of ISDN they had had during the study (mean dose 29 mg) for a mean period of 5.6 months before retesting using the same protocol. Compared to placebo, exercise time after sublingual nitroglycerin increased 56% (P less than 0.001) initially and 51% (P less than 0.001) at retest. Compared to placebo, exercise time increased 58% (P less than 0.05) initially and 58% (P less than 0.005) at retest 1 hour after ISDN, 38% (P less than 0.05) initially and 27% (P less than 0.005) at retest 3 hours after ISDN, and 13% (NS) initially and 21% (P less than 0.02) at retest five hours after ISDN. The mean exericse times initially and at retest were not significantly different. Hemodynamic changes (decrease in systolic blood pressure and increase in heart rate) at 15 min persisted through 300 min after ISDN during both initial testing and during retesting. However, these changes were significantly less during retesting. We conclude that a partial tolerance to the hemodynamic effects of the drug develops after chronic use of high dose oral ISDN but that the antianginal efficacy of both sublingual nitroglycerin and oral ISDN is unimpaired.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 406098     DOI: 10.1161/01.cir.56.2.205

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

Review 1.  An update on nitrate tolerance: can it be avoided?

Authors:  S R Maxwell; M J Kendall
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

Review 2.  Update on nitrate tolerance.

Authors:  J O Parker
Journal:  Br J Clin Pharmacol       Date:  1992       Impact factor: 4.335

Review 3.  Cardiovascular drug therapy in the elderly: benefits and challenges.

Authors:  Jerome L Fleg; Wilbert S Aronow; William H Frishman
Journal:  Nat Rev Cardiol       Date:  2010-10-26       Impact factor: 32.419

Review 4.  Causes and problems of nonresponse or poor response to drugs.

Authors:  P Salvà Lacombe; J A García Vicente; J Costa Pagès; P Lucio Morselli
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 5.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance.

Authors:  S Silber; A C Vogler; K H Krause; K Theisen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Haemodynamics and plasma concentrations following sublingual GTN and intravenous, or inhaled, isosorbide dinitrate.

Authors:  W Culling; H Singh; A Bashir; B E Griffiths; J J Dalal; D J Sheridan
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

Review 8.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 9.  Haemodynamic aspects of nitrate tolerance.

Authors:  L Erhardt
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  Avoidance of tolerance and lack of rebound with intermittent dose titrated transdermal glyceryl trinitrate. The Transdermal Nitrate Investigators.

Authors:  K M Fox; H J Dargie; J Deanfield; A Maseri
Journal:  Br Heart J       Date:  1991-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.